NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn ...

Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA ...

Despite this potential, the stock has fallen by 25% in the past 12 months -- so is it a bargain buy right now? During the ...

Within that group, biotechnology giant Amgen (NASDAQ: AMGN) has been the best-performing stock in 2025, returning an ...

2025年3月15日（GLOBE NEWSWIRE）——Faruqi & ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

2025年3月17日，罗森律师事务所宣布，针对默克公司（Merck & Co., ...

Merck is planning layoffs in Pennsylvania as part of a multi-year plan to wind down operations at a manufacturing plant in ...

NEW YORK, NY / ACCESS Newswire / March 25, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and ...

The HPV vaccine, called Gardasil-9 — which has no live virus and is completely non-infectious — protects against the six types of HPV most likely to cause cancer, Eckert says. (These are strains 6, 11 ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) and reminds investors of the April 14, ...